Didanosine: Difference between revisions
Gerald Chi (talk | contribs) |
Gerald Chi (talk | contribs) m (→US Brand Names) |
||
| Line 13: | Line 13: | ||
==US Brand Names== | ==US Brand Names== | ||
VIDEX<sup>®</sup> | VIDEX<sup>®</sup>, VIDEX EC<sup>®</sup> | ||
==FDA Package Insert== | ==FDA Package Insert== | ||
Revision as of 04:19, 5 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Overview
Didanosine (2′,3′-dideoxyinosine,DDI) is sold under the trade names Videx and Videx EC. It is a reverse transcriptase inhibitor, effective against HIV and used in combination with other antiretroviral drug therapy as part of highly active antiretroviral therapy (HAART).
Category
Antiretroviral
US Brand Names
VIDEX®, VIDEX EC®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages
Mechanism of Action
Didanosine (ddI) is a nucleoside structural analogue of guanosine. It differs from other nucleoside analogues, because it does not have any of the regular bases, instead it has hypoxanthine attached to the sugar ring. Within the cell, ddI is phosphorylated to the active metabolite of dideoxyadenosine triphosphate, ddATP, by cellular enzymes. Like other anti-HIV nucleoside analogs, it acts as a chain terminator by incorporation and inhibits viral reverse transcriptase by competing with natural Adenosine triphosphate (dATP).